CHF 40,000 for a transformative technology for brain surgery, molecular intelligence for the chemical industry, and phage therapies to fight antibiotic-resistance
25.10.2024
Clee Medical, Molucent, Precise Health were selected at Venture Kick's second financial and entrepreneurial support stage. Their projects provide a transformative technology for brain surgery by combining novel intraoperative imaging with AI & machine learning to make access to the brain faster, easier, and safer; develop comprehensive, customized, and accurate property databases, which are directly accessible to chemical engineers through their daily tools; and offer phage therapies to combat critical antibiotic-resistant infections.
 |
 |
 Clee Medical: Matthew Lapinski
|
|
 Molucent: CEO Dr. Johannes Schilling, CSO Dr. Philipp Rehner, CTO Dr. Gernot Bauer, Scientific Advisor Dr. Benedikt Winter, and Scientific Advisor Prof. Dr. André Bardow
|
|
 Precise Health: CEO Dr. José Luis
|
|
Clee Medical: transformative technology for brain surgery
Clee Medical is developing a transformative technology for brain surgery by combining novel intraoperative imaging with AI & machine learning to make access to the brain faster, easier, and safer
Matt Lapinski and Dr. Abed Hammoud founded Clee Medical. Matt brings his startup experience earned over a decade in Boston's medical device startup scene while Abed brings 25+ years of driving innovation in stereotactic neurosurgery, including leading companies purchased by the largest players in the world. The technology is being developed for a substantial market with a forecast service obtainable market of CHF 1.3B.
The Venture Kick funding will be used to strengthen the IP portfolio and plan a first-in-human clinical study.
Molucent: Transforming the chemical industry through molecular intelligence
The transition of the chemical industry to a sustainable carbon economy requires new products, processes, and value chains. Designing this new carbon economy relies on accurate physical property data for the molecules involved. However, this data is lacking for many molecules and even more for their mixtures, resulting in a massive data gap hindering the rapid transition to a sustainable carbon economy.
Molucent, a startup to be founded by Gernot Bauer, Philipp Rehner, and Johannes Schilling with scientific advisors Benedikt Winter and Prof. André Bardow, aims to tackle this issue. Leveraging their research at ETH Zurich, the founders have developed an advanced machine-learning-powered property prediction tool that combines natural language processing with modern physics-based property models. This innovative solution allows Molucent to provide comprehensive, customized, and accurate property databases, which are directly accessible to chemical engineers through their daily tools. With its user-friendly solution, Molucent intends to serve customers in the chemical and pharmaceutical industries.
The Venture Kick funds will be instrumental in defining Molucent’s first pilot projects with chemical companies and process simulation software developers and establishing the company’s structure for incorporation.
Precise Health: Developing Phage Therapies to combat critical antibiotic-resistant infections
Antimicrobial resistance (AMR) is rising due to the overuse and misuse of broad-spectrum antibiotics, leading to treatment failures and increased healthcare risks. It has caused 1.27 million deaths annually and poses an additional economic burden of up to USD1 trillion by 2030.
Precise Health is building a platform for the development of personalized phage therapies to target resistant bacteria without harming the beneficial microbiota, reducing AMR. Co-funders are CEO Dr. José Luis, CSO Dr. Paul Tetteh , both graduated from EPFL, and COO Dr. Hale Bila from ETHZ. Their preliminary phage products, specifically designed to combat inflammatory skin conditions (acne, atopic dermatitis) as a proof-of-concept have shown over 90% efficacy against relevant bacterial strains. These PoC products will serve as a market entry point, with broader applications to follow for other bacterial infections affected by AMR such as vaginal infections.
The Venture Kick support will enable the filing of the 3rd IP.
Clee Medical is developing a transformative technology for brain surgery by combining novel intraoperative imaging with AI & machine learning to make access to the brain faster, easier, and safer
Matt Lapinski and Dr. Abed Hammoud founded Clee Medical. Matt brings his startup experience earned over a decade in Boston's medical device startup scene while Abed brings 25+ years of driving innovation in stereotactic neurosurgery, including leading companies purchased by the largest players in the world. The technology is being developed for a substantial market with a forecast service obtainable market of CHF 1.3B.
The Venture Kick funding will be used to strengthen the IP portfolio and plan a first-in-human clinical study.
Molucent: Transforming the chemical industry through molecular intelligence
The transition of the chemical industry to a sustainable carbon economy requires new products, processes, and value chains. Designing this new carbon economy relies on accurate physical property data for the molecules involved. However, this data is lacking for many molecules and even more for their mixtures, resulting in a massive data gap hindering the rapid transition to a sustainable carbon economy.
Molucent, a startup to be founded by Gernot Bauer, Philipp Rehner, and Johannes Schilling with scientific advisors Benedikt Winter and Prof. André Bardow, aims to tackle this issue. Leveraging their research at ETH Zurich, the founders have developed an advanced machine-learning-powered property prediction tool that combines natural language processing with modern physics-based property models. This innovative solution allows Molucent to provide comprehensive, customized, and accurate property databases, which are directly accessible to chemical engineers through their daily tools. With its user-friendly solution, Molucent intends to serve customers in the chemical and pharmaceutical industries.
The Venture Kick funds will be instrumental in defining Molucent’s first pilot projects with chemical companies and process simulation software developers and establishing the company’s structure for incorporation.
Precise Health: Developing Phage Therapies to combat critical antibiotic-resistant infections
Antimicrobial resistance (AMR) is rising due to the overuse and misuse of broad-spectrum antibiotics, leading to treatment failures and increased healthcare risks. It has caused 1.27 million deaths annually and poses an additional economic burden of up to USD1 trillion by 2030.
Precise Health is building a platform for the development of personalized phage therapies to target resistant bacteria without harming the beneficial microbiota, reducing AMR. Co-funders are CEO Dr. José Luis, CSO Dr. Paul Tetteh , both graduated from EPFL, and COO Dr. Hale Bila from ETHZ. Their preliminary phage products, specifically designed to combat inflammatory skin conditions (acne, atopic dermatitis) as a proof-of-concept have shown over 90% efficacy against relevant bacterial strains. These PoC products will serve as a market entry point, with broader applications to follow for other bacterial infections affected by AMR such as vaginal infections.
The Venture Kick support will enable the filing of the 3rd IP.